The General Hospital Medical Center
Integrated Pathology View - April 13, 1998

Report to Patient

Sam Patient          (74 year old Male)
000-00-000
Prostate Cancer
PSA Level Status Post Prostate Resection
Clinical History:
The patient is a 74 year old diagnosed with Prostatic Adenocarcinoma in January 1997.  Radical Prostectomy February 1997.  Followed by PSA.
Relevant Pathology Findings:  Serum PSA Test October 12 1994
Serum PSA Test  November 1 1995
Serum PSA Test November 10 1996
Prostate Biopsy January 07 1997
Prostate Resection Feb. 10 1997
Serum PSA Test March 4, 1997
Serum PSA Test June 22 1997
Serum PSA Test Nov. 20 1997
Prostate Resection (complete report)- Feb. 10 1997
Diagnosis:
Prostate, Nerve Sparing Prostectomy with Pelvic Lymph Node Dissection:
Infliltrating Adenocarcinoma of the Prosate
- Gleason Score 3+2=5
- Pathologic Stage T2, N0, M0
- Tumor is NOT identified in the margin of resection
- Tumor measures 1.5 cm and is confined to the left lobe
- Capsular Invasion is NOT identified.
- Angiolymphatic invasion is NOT identified
- Focal Perineural Invasion is identified
- Mulitfocal PIN is identied
- Ten (10) of ten (10) pelvic lymph nodes are negitive for metastatic adenocarcinoma.
- Right and Left Seminal Vesicle are negitive for tumor.
                                Explaination of Diagnositic Terms
Serum PSA Profile

 

     |
     |                 * - 12 ng/dl
     |
     |                 
     |          * -3.9
     |_*________*____*____*___*-0.0 ng/dl


                        Explaination of the Serum PSA Test

lion.wmf (3606 bytes) turtle.wmf (6870 bytes)         more images Most recent PSA - April 13, 1998

                  Total Serum PSA - 0.0 ng/dl
                         
Prognostic and Management Markers:
Major prognostic markers for patients status post radical prostectomy for prostatic adenocarcinoma include pathologic stage, Gleason grade and Total Serum PSA levels.
Patients like you at UPMC:
Search of our database finds 39 males, age 70-75, with similar Surgical Pathology findings (Stage 2B, Gleason 3+2=5) that have had undetectable Serum PSA one year after Radical Prostectecomy. 89% have had no evidence of recurrence with a average followup time of 2.2 years (1.1 - 5.0 years).  NOTE:  This is a statistical view of patients are UPMC.   Every patient is different as is every theraputic circumstance.   Laboratory results make up only a part of the each patients clinical situation and cannot predict outcomes in individual cases.
Pathologist's Report:
This patient had moderately differenciated adenocarcinoma that did not invade the capsule, had no angio-lymphatic invasion and was completely removed.  Serum PSA has been undetectable for one year post surgery.  Laboratory data indicate that this pateint has a very high likelyhood of cure.  Laboratory data needs to be combined with all clinical data to generate a complete clinical picture. 
Useful WWW Links for patients with   prostatic carcinoma:
National Cancer Institue's PDQ information for patients with Prostate cancer:
The University of Pennslyvania's OncoLink:
National Cancer Institute Cancer Information Service: 1-800-4-CANCER
Contact Pathologist: 
Joe Pathologist Tel 647 4774
Pg   232 2332
joe@pathology .edu